Moderna takes over $1 billion in deposits for coronavirus vaccine

30 October 2020

Stock in US biotech Moderna (Nasdaq: MRNA) ended the day up nearly 8.5% on Thursday, following a business update in which the firm said it was “actively preparing” for the launch of its COVID-19 vaccine.

Moderna is developing a novel mRNA-based vaccine which, if approved, would enable a relatively rapid deployment of finished product to customers around the world.

The firm said it had received $1.1 billion of customer deposits for supply of mRNA-1273 in the third quarter of 2020 - money which has been booked as deferred revenue.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK